Literature DB >> 17573762

European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology.

M Arbyn1, A Herbert, U Schenck, P Nieminen, J Jordan, E Mcgoogan, J Patnick, C Bergeron, J-J Baldauf, P Klinkhamer, J Bulten, P Martin-Hirsch.   

Abstract

The current paper presents an annex in the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening. It provides guidance on how to make a satisfactory conventional Pap smear or a liquid-based cytology (LBC) sample. Practitioners taking samples for cytology should first explain to the woman the purpose, the procedure and how the result will be communicated. Three sampling methods are considered as acceptable for preparing conventional Pap smears: (i) the cervical broom; (ii) the combination of a spatula and an endocervical brush; and (iii) the extended tip spatula. Smear takers should take care to sample the entire circumference of the transformation zone, to quickly spread the cellular material over a glass slide, and to fix the preparation within a few seconds to avoid drying artefacts. According to local guidelines, one of these three methods may be preferred. Sampling with a cotton tip applicator is inappropriate. Similar procedures should be followed for sampling cells for LBC, but only plastic devices may be used. The collected cells should be quickly transferred into a vial with fixative liquid according to the instructions of the manufacturer of the LBC system. Subsequently, the slide or vial and the completed request form are sent to the laboratory for cytological interpretation.

Entities:  

Mesh:

Year:  2007        PMID: 17573762     DOI: 10.1111/j.1365-2303.2007.00464.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  18 in total

1.  [Quality of conventional PAP smears. Quality assessment and motivation for improvement].

Authors:  P Regitnig; A Nader; H Wiener
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.

Authors:  C E Depuydt; I H Benoy; J F A Beert; A M Criel; J J Bogers; M Arbyn
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

4.  Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials.

Authors:  P E Castle; J Bulten; M Confortini; P Klinkhamer; A Pellegrini; A G Siebers; G Ronco; M Arbyn
Journal:  BJOG       Date:  2010-08       Impact factor: 6.531

5.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document.

Authors:  M Arbyn; A Anttila; J Jordan; G Ronco; U Schenck; N Segnan; H Wiener; A Herbert; L von Karsa
Journal:  Ann Oncol       Date:  2010-03       Impact factor: 32.976

6.  Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.

Authors:  Markus Schmitt; Christophe Depuydt; Ina Benoy; Johannes Bogers; Jerome Antoine; Marc Arbyn; Michael Pawlita
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

7.  Early detection of cervical carcinomas: finding an overall approach.

Authors:  Nicolas Wentzensen; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2008-09-12       Impact factor: 5.594

8.  The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines.

Authors:  Andrzej Nowakowski; Marek Cybulski; Andrzej Śliwczyński; Arkadiusz Chil; Zbigniew Teter; Przemysław Seroczyński; Marc Arbyn; Ahti Anttila
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

9.  Changes in type-specific human papillomavirus load predict progression to cervical cancer.

Authors:  Christophe E Depuydt; Arnold M Criel; Ina H Benoy; Marc Arbyn; Annie J Vereecken; Johannes J Bogers
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

10.  Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Authors:  D T Geraets; K Cuschieri; M N C de Koning; L J van Doorn; P J F Snijders; C J L M Meijer; W G V Quint; M Arbyn
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.